SIX1 interacts with EYA to form a bipartite transcription factor essential for mammalian development. Loss of function of this complex causes branchio-oto-renal (BOR) syndrome, whereas re-expression of SIX1 or EYA promotes metastasis. Here we describe the 2.0-Å structure of SIX1 bound to EYA2, which suggests a new DNA-binding mechanism for SIX1 and provides a rationale for the effect of BOR syndrome mutations. The structure also reveals that SIX1 uses predominantly a single helix to interact with EYA. Substitution of a single amino acid in this helix is sufficient to disrupt SIX1-EYA interaction, SIX1-mediated epithelial-mesenchymal transition and metastasis in mouse models. Given that SIX1 and EYA are overexpressed in many tumor types, our data indicate that targeting the SIX1-EYA complex may be a potent approach to inhibit tumor progression in multiple cancer types.
a r t i c l e s SIX1 belongs to the mammalian Six family of homeobox genes, which are homologs of the Drosophila sine oculis (so) gene. These genes encode transcription factors that have vital roles in proliferation and survival of progenitor cells during organogenesis 1 . The Six family consists of six members (SIX1-6) that share a homologous Six-type DNA-binding homeodomain (HD) and a conserved Six domain (SD), which is involved in protein-protein interactions 2 .
Because SIX1 is a transcription factor that lacks intrinsic activation domains, it requires the EYA family of cofactors to mediate transcriptional activation. The four EYA proteins (EYA1-4) are mammalian homologs of the Drosophila eyes absent (eya) gene and are characterized by a highly conserved ~270 amino acid C-terminal EYA domain (ED) 3 , which interacts with the SD of SIX1 (ref. 2) . The ED contains signature motifs of the haloacid dehalogenase (HAD) hydrolases and has Mg 2+ -dependent protein tyrosine phosphatase activity [4] [5] [6] . The crystal structure of the EYA2ED reveals that it is composed of the catalytic subdomain and a helix-bundle motif that is hypothesized to have a role in protein-protein interactions 7 . Like SIX1, EYA proteins are critical for the development of multiple organs, in part by promoting proliferation and survival of progenitor-cell populations 4 . Loss of function of SIX1 and EYA is implicated in multiple developmental disorders 8, 9 . Mutations in either SIX1 or EYA1 cause BOR syndrome, an autosomal-dominant developmental disorder characterized by hearing loss, branchial fistulae and renal anomalies 8 . Mutations in EYA4 are also the cause of sensorineural hearing loss within the DFNA10 locus [10] [11] [12] . Additionally, mutations in EYA4 have been shown to cause cardiomyopathy 12 , and SIX1 and EYA have recently been implicated in cardiac hypertrophy 13 .
SIX1 is downregulated after organ development is complete; thus its expression is low or undetectable in most normal adult tissues 14 . However, SIX1 is re-expressed in a number of cancers, and its overexpression strongly correlates with disease progression in many tumor types [15] [16] [17] [18] [19] [20] [21] . Our laboratory has shown that SIX1 overexpression in mouse mammary glands leads to highly aggressive mammary tumors that display oncogenic epithelial-mesenchymal transition (EMT) and stem cell phenotypes 22 . Additionally, we have shown that SIX1 can induce EMT and cancer stem cell phenotypes as well as metastasis through upregulation of the TGF-β signaling pathway 16, 23 . Finally, we have recently demonstrated that SIX1 affects metastasis through additional mechanisms including upregulation of VEGF-C and induction of lymphangiogenesis 24 . These observations suggest that SIX1 is a global regulator of tumor progression and that disruption of SIX1 function would be therapeutically relevant in many different cancers. Indeed, knockdown of SIX1 in breast 24 and hepatocellular carcinoma 25 , as well as in rhabdomyosarcoma 15 , leads to a dramatic decrease in tumor size and metastasis in animal models. Because it is traditionally difficult to target transcription factor-DNA interactions 26 , we set out to investigate whether inhibiting the transcriptional complex formed by SIX1 and its EYA coactivator would serve as a viable approach to inhibit SIX1-mediated tumor progression.
Multiple studies indicate that SIX1 and EYA act together in cancer. Overexpression of both SIX1 and EYA is observed in Wilms' tumor 27 , acute leukemia 28 and malignant peripheral nerve-sheath tumors 29 . SIX1 and EYA2 have also both been independently implicated in ovarian cancer 21, 30 . In breast tumors, high expression of SIX1 and EYA2 together (but neither gene alone) significantly correlates with reduced time to relapse and metastasis and with decreased survival 31 . Furthermore, SIX1 and EYA have independently been shown to contribute to metastasis in breast cancer cells 16, 32 , and EYA2 is required for many of the SIX1-induced prometastatic phenotypes in breast cancer cell lines 31 . However, the coordinated action of the two proteins a r t i c l e s in cancer has never been shown in vivo, and it remains controversial whether the direct physical interaction between SIX1 and EYA is required, because EYA's phosphatase activity is critical for breast cancer-associated metastasis, and this function of EYA may be independent of SIX1 (ref. 32) . In spite of the clear importance of the SIX1-EYA complex in development and disease, the atomic structure of SIX1, the molecular details of the SIX1-EYA interaction and the functional significance of their direct physical interaction in cancer have remained unexplored. To fill these voids, we performed structural and functional analyses of the human SIX1-EYA2 complex.
RESULTS

The SIX1-EYA2ED structure
To gain insight into the molecular details of the SIX1-EYA interaction and the atomic structure of SIX1, we determined the crystal structure of the human SIX1-EYA2ED complex. We employed the maltose-binding-protein fusion technique with surface-entropy reduction that uses maltose-binding proteins with surface mutations to aid in crystallization 33 . We fused MBP_B (E172A N173A mutant, which will be referred to as MBP for simplicity) to the N terminus of a SIX1 construct that includes both the SD and HD (residues 1-189) but excludes the predicted unstructured C terminus ( Fig. 1a) . We confirmed that the MBP-SIX1 protein was functionally active in a DNA-binding assay (Supplementary Fig. 1) .
We determined the structure of MBP-SIX1 in complex with EYA2ED, and the final model was refined to 2.0 Å ( Table 1) . The MBP-SIX1-EYA2ED crystal contains one copy of each protein in the asymmetric unit ( Fig. 1b) . Three regions (residues 40-45, 124-133 and 186-189) in SIX1 and two regions (residues 253-267 and 356-371) in EYA2ED were disordered and not visible in the electron density map.
The structure of SIX1 is organized into two distinct domains (SD and HD) connected by a flexible linker (Fig. 1c) . The SD consists of six α-helices, α1-α6 (Fig. 1c) , and does not show structural homology with any other proteins in a DALI server search 34 . The HD of SIX1 contains three α-helices (α7-α9) forming the signature HD fold 35 . The N-terminal arm, as expected, is flexible in the absence of DNA and is therefore missing from the electron density (dotted lines in Fig. 1c) .
A putative DNA-binding mechanism for SIX1 Canonical HD proteins interact with DNA through a mechanism in which the HD's recognition helix (α3 in canonical HDs or α9 in SIX1) binds the major groove, and the N-terminal arm contacts the minor groove 35 . The N-terminal arm typically contains basic residues at positions 2 and 3 that form hydrogen bonds with the DNA backbone, and an showing the proximity of α6 of SIX1 (black box) to the DNA major groove. (e) Conservation of amino acids in the α6 helix of SIX1 among Six-family members. Asterisk, strictly conserved residues; colon, residues with strongly similar properties; period, residues with weakly similar properties. Residues mutated in BOR are indicated in red. npg a r t i c l e s
Molecular details of the SIX1-EYA interface
The structure of the SIX1-EYA2ED complex unexpectedly reveals that SIX1 interacts with the HAD catalytic domain and not the helixbundle motif of the EYA2ED, as was previously proposed ( Fig. 1b) 7 , with a combined buried surface area of 1,600 Å 2 (~800 Å 2 on the SIX1 interface and ~800 Å 2 on EYA). Notably, the interaction between SIX1 and EYA is mediated predominantly by a single SIX1 helix (α1) that fits into a binding groove on EYA2ED through a combination of hydrophobic interactions, hydrogen bonds and salt bridges ( Fig. 2a-c) . This interaction mode demonstrates an unexpected resemblance to two other protein-protein interactions (p53-MDM2 and BH3-BCL-XL) 43, 44 , both of which use an amphipathic α-helix to bind in a hydrophobic groove and both of which have been successfully targeted by small molecules as potential cancer therapeutics 45, 46 . The binding groove in EYA is formed with the β1 and β4 strands constituting the floor and the β5-turn-α12 structure constituting the binding-groove wall (Fig. 2a) . The binding groove is largely hydrophobic and lined with Val496, Val498, Pro516, Phe517, Trp518 and Leu538 ( Fig. 2b , orange surface). Cys16 and Val20 from SIX1 α1 protrude into the hydrophobic groove ( Fig. 2b) . There are several hydrogen bonds between SIX1 α1 and EYA2ED including between the sulfhydryl group of the centrally located cysteine, SIX1 Cys16, and the carbonyl oxygen of EYA2ED Phe517, whereas the hydrophobic binding groove is flanked by two salt bridges (Fig. 2c) . The N-terminal tail immediately upstream of α1 and the α2 helix of SIX1 forms additional van der Waals interactions with a small surface patch on EYA2ED ( Fig. 2b , gray surface). Multiple sequence alignments of Sixand Eya-family members from diverse eukaryotic organisms show a high degree of sequence conservation in their interacting regions, highlighting the importance of these residues for proper function of the complex (Supplementary Figs. 2 and 3) .
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arginine at position 5 that makes extensive contacts with the nucleoside base and sugar. However, the N-terminal arm of SIX1 lacks basic amino acids at these three positions, with two of these residues replaced with acidic residues. This suggests that the N-terminal arm of SIX1 does not bind the minor groove in the canonical manner, if it binds this groove at all. Indeed, deletion of the N-terminal arm of SIX6 only slightly decreases its ability to bind DNA 36 , whereas in typical HD-containing proteins, deletion of the N-terminal arm dramatically decreases binding affinity [36] [37] [38] . Recent analyses have shown that regions outside of the HD are necessary to recognize DNA sequences bound by SIX1 within the cell 39 , and regions upstream of the N-terminal arm enhance DNA binding in SIX4 (ref. 40 ) and SIX5 (ref. 41 ). Finally, the HDs of SIX2 and SIX6 alone are unable to bind the MEF3 consensus sequence 36 . These observations led to the hypothesis that the DNA-binding activity of the Six family of homeoproteins extends beyond the HD. Several lines of evidence from our structural and biochemical analyses support this hypothesis. First, when the SIX1 structure is superimposed on MATα-DNA (PDB 1K61, chain A), a known homeodomain-DNA complex structure, α6 of the SD (the first helix upstream of the HD) could easily interact with the DNA major groove with a minor positional adjustment (which is feasible because the SD and HD are connected by a flexible linker) ( Fig. 1c,d) . Second, this ten-residue helix (sequence AVGKYRVRRK) contains five positively charged residues, and amino acids in this helix are highly conserved in the Six family ( Fig. 1e and Supplementary Fig. 2) . Third, three SIX1 residues that are mutated in BOR syndrome (Val106, Arg110 and Arg112) and that we previously demonstrated to abrogate DNA binding 42 reside within this helix ( Fig. 1e and Supplementary Fig. 2) . Taken together, these observations suggest a new DNA-binding mechanism for Six-family proteins that involves both the HD and SD. Formal proof of this hypothesis awaits future analyses of the structure of SIX1 bound to DNA. To confirm the binding interface, we performed structure-based mutagenesis of SIX1 and EYA2ED. We have previously reported that a naturally occurring SIX1 BOR mutant, V17E, disrupts the formation of the SIX1-EYA complex 42 . In the crystal structure, Val17 resides in the middle of the SIX1 α1 helix and extends into the binding interface to make van der Waals contacts with Tyr537 in EYA (Fig. 2b) , which provides a clear explanation of why mutating this residue to a glutamic acid disrupts the ability of SIX1 to bind EYA. In the current study, we have mutated the centrally located cysteine residue (C16R) in SIX1 and two EYA2ED residues (P516R and A532R) that reside at the interface (Fig. 2b) . We found that SIX1 C16R and EYA2ED A532R completely abolish complex formation, whereas EYA2ED P516R severely compromises SIX1-EYA2ED binding, on the basis of size-exclusion chromatography analyses (Fig. 2d) . These observations validate the SIX1-EYA binding interface and demonstrate that single point mutations can markedly reduce SIX1-EYA binding.
Structural basis of BOR mutations
EYA1 is the most commonly mutated gene in BOR syndrome, and there are at least 14 reported missense mutations within the ED of EYA1 (refs. 8,47-49) . Although our structure was determined with the ED of EYA2, EYA1ED and EYA2ED share over 90% sequence similarity (Supplementary Figs. 3 and 4) . Notably, mammalian EYA1 and EYA2 can both complement Drosophila eya mutations with comparable efficiency 50, 51 , and EYA1 and EYA2 have been shown to be functionally redundant during myogenesis 52 . Furthermore, of the 14 BOR mutations found in EYA1ED, 12 residues are identical between EYA1 and EYA2 (Supplementary Figs. 3 and 4) . These data suggest that our SIX1-EYA2ED structure could be used as a framework to predict the molecular mechanisms of the EYA1 BOR mutants, which could serve as valuable models for directing future functional studies.
We first evaluated the impact of each missense mutation on protein structure and stability by using Site-Directed Mutator (SDM), a program that was validated with 855 mutations from 17 different proteins 53 . SDM predicts that 6 of the 14 missense mutations destabilize the EYA2ED structure ( Table 2 ). The remaining mutations (which we will refer to as nondestabilizing mutants) that are solvent exposed may affect protein function by disrupting substrate binding, catalysis or binding to SIX1 or other cofactors. One of these mutations, E309V, was previously predicted to be on the SIX1-binding surface 7 . However, our structure demonstrates that this residue is in fact distant from the actual SIX1-EYA interface (Fig. 3a) . Instead, this amino acid resides on the same face as the active site pocket (Fig. 3a) , which leaves open the possibility that it is involved in substrate binding. This residue is conserved in all human and mouse Eya-family members as well as in Drosophila eyes absent, which is consistent with its potential importance for EYA function (Supplementary Fig. 3) . Another nondestabilizing mutant, N433P, resides in the middle of α8 of the catalytic domain. Though not predicted by SDM to destabilize the overall protein structure, it probably alters the secondary structure of α8, which resides behind the active site, and its disruption could affect phosphatase activity. Supporting this hypothesis, EYA proteins containing this mutation are able to bind SIX1 in cells 54, 55 but have severely compromised phosphatase activity 55, 56 . Two other nondestabilizing mutants, D375G and R386Q, both mapped to α5 near a flexible loop (residues 356-371) and may represent residues involved in interactions with a yet-to-be identified cofactor. Indeed, Asp375 and a positively charged amino acid at position 386 are conserved across all Eya-family members (Supplementary Fig. 3) .
Three BOR mutations (V496E, ∆V499 and L529P) map to secondary structures that make up the SIX1 binding groove in EYA ( Fig. 3a  and Supplementary Fig. 3 ). EYA2ED Val496 resides at the beginning of β4, which forms part of the floor of the hydrophobic binding groove and makes van der Waals contacts with SIX1 Gln23 and Gly24. This mutation to a charged amino acid with an elongated side chain will probably result in electrostatic and steric clashes with SIX1. EYA2ED Val499 is not solvent accessible and is located in the center of β4, and deletion of this residue would be predicted to alter the structure of this β-strand. EYA2ED Leu529 resides in the middle of α12, and a leucine-to-proline change probably disrupts the secondary structure of this helix; indeed, SDM predicts that a proline in this buried position would destabilize the protein ( Table 2) .
Missense mutations in SIX1 have also been identified in BOR patients 9 . Our previous functional analyses on six of these mutations demonstrate that five of them disrupt DNA binding 42 . All five mutations map either to the HD itself (Y129C and ∆E133) or to α6 in the SD (V106G, R110W and R112C) ( Fig. 3b and Supplementary  Fig. 2) . As stated previously, the single SIX1 BOR mutation that we found to inhibit binding to EYA, V17E, resides on the SIX1 helix (α1) that interacts with EYA ( Figs. 2b and 3b) . Finally, SDM predicts that one of the SIX1 mutations that we were unable to express efficiently, H73P, would deleteriously affect protein stability ( Table 2) . npg a r t i c l e s
SIX1-EYA binding is required for metastatic phenotypes
In contrast to the loss-of-function mutations observed in BOR, overexpression of either SIX1 or EYA has independently been associated with the development and progression of numerous cancers. For example, SIX1 and EYA have been shown to induce pro-EMT characteristics and metastasis in multiple breast cancer studies 16, 31, 32 . However, the relevance of the direct physical interaction between SIX1 and EYA in metastasis has remained unclear, particularly because EYA has intrinsic phosphatase activity that may act independently of its coactivator function with SIX1 in promoting metastasis 32 . To address this question, we capitalized on the information obtained from the structure and biochemical analyses of the SIX1-EYA complex and generated stably transfected MCF7 cells overexpressing either wildtype SIX1 (SIX1 WT), SIX1 V17E (the mutation that abrogates SIX1 binding to EYA but still allows for DNA binding 42 ), SIX1 ∆E133 (a mutation that abrogates DNA binding but not EYA binding 42 ) or chloramphenicol acetyltransferase as a control (MCF7-Ctrl). Of note, the SIX1 V17E mutant is likely to inhibit binding to all EYAs, because SIX1 can bind all members of the Eya family 11, 42, 57 , and residues involved in SIX1 binding are well conserved (identical or similar) in all Eya-family members (Supplementary Fig. 3) . To control for insertion-site effects, three stable clonal isolates (unpooled) for each construct were selected with similar SIX1 expression ( Supplementary  Fig. 5 ) and were used for all subsequent experiments. We first evaluated whether the direct SIX1-EYA interaction is essential for SIX1-mediated TGF-β signaling, a pathway that is required for the EMT and metastatic phenotypes induced by SIX1 in MCF7 breast cancer cells 16 . Although SIX1 WT is able to increase the levels of phospho-SMAD3 protein (an effector of TGF-β signaling) and to increase TGF-β signaling (as measured by the 3TP-Lux luciferase reporter that contains SMAD-responsive elements from the plasminogen-activator inhibitor-1 and collagenase I genes 58 ), both the SIX1-EYA binding mutant (V17E) and the DNA-binding mutant (∆E133) are unable to activate this signaling pathway (Fig. 4a,b) . These data demonstrate that the direct interaction of SIX1 with EYA (and, as expected, of SIX1 with DNA) is required to activate TGF-β signaling.
We next examined whether the SIX1-EYA interaction is required to induce EMT-like characteristics by analyzing the aforementioned cell lines for expression of the epithelial marker cytokeratin 18 and the mesenchymal marker fibronectin. Consistent with previous observations 16 , overexpression of SIX1 WT leads to decreased expression of cytokeratin 18 and concomitant increased expression of fibronectin (Fig. 4c) . However, in the MCF7-V17E and MCF7-∆E133 cells, expression of cytokeratin 18 remained high, and expression of fibronectin remained low, similar to what is observed in MCF7-Ctrl cells. Similarly, expression of SIX1 V17E or ∆E133 in MCF7 cells fails to significantly decrease cell-matrix adhesion to collagen I, collagen IV and laminin (Fig. 4d) . In contrast, expression of SIX1 WT significantly decreases adhesion to all three matrices, another characteristic of EMT. In all cases, the SIX1 V17E and ∆E133 mutants behave similarly to the MCF7-Ctrl cells, which strongly suggests that a direct interaction between SIX1 and EYA is required to mediate TGF-β signaling, ultimately enabling pro-EMT characteristics in cultured cells.
SIX1-EYA binding is required for SIX1-mediated metastasis
We have previously demonstrated that the involvement of SIX1 in later stages of metastasis is dependent on the induction of TGF-β signaling 16 . Additionally, there is increasing evidence for EMT as an important mechanism of the metastatic process 59 . In the current work, we show that the SIX1-EYA interaction (and as expected, the SIX1-DNA interaction) is required for enhanced TGF-β signaling and pro-EMT characteristics (Fig. 4) . To determine whether this interaction is also necessary for enhanced late-stage metastasis induced by SIX1, we performed experimental metastasis assays using MCF7-Ctrl, -SIX1 WT, -V17E and -∆E133 cells tagged with firefly luciferase npg a r t i c l e s to visualize in vivo metastatic spread. Three clonal isolates of each line were injected into the arterial bloodstream of nude mice. In agreement with previous work 16 , the MCF7-SIX1 WT cells metastasized significantly more than did MCF7-Ctrl cells, as measured by total body bioluminescence ( Fig. 5a,b) . Additionally, mice injected with MCF7-SIX1 WT cells had an overall shortened survival compared to mice injected with MCF7-Ctrl cells (Fig. 5c) . Notably, the SIX1 V17E and SIX1 ∆E133 mutants did not enhance metastasis above that observed with MCF7-Ctrl cells (Fig. 5a,b ) or alter overall survival (Fig. 5c) . These data demonstrate that disruption of the SIX1-EYA interaction potently inhibits the ability of SIX1 to induce metastasis.
DISCUSSION
Although it has traditionally been difficult to target transcription factors in the clinic, inhibiting the protein-protein interaction in these transcriptional complexes has been increasingly realized as a strategy that holds great promise 26 . Our crystal structure reveals that SIX1 uses predominantly a single amphipathic α-helix to bind a hydrophobic cleft in EYA, a binding mechanism that is highly similar to two other protein-protein interactions that have been successfully targeted with small molecules as potential cancer therapeutics. These small molecules include nutlin, which is an efficient p53-MDM2 interaction inhibitor 45 , and navitoclax, which inhibits the interactions between members of the B-cell lymphoma 2 (Bcl-2) family of proteins 46 . Here we demonstrate that a single amino acid mutation on the amphipathic α-helix of SIX1 that can disrupt the SIX1-EYA interaction potently inhibits SIX1-mediated TGF-β signaling, EMT and metastasis. Our structure and functional data strongly suggest that disruption of the SIX1-EYA transcriptional complex by using small molecules may be a feasible approach in developing new anticancer agents. Such anticancer therapeutics could potentially be effective in breast cancer, Wilms' tumor, acute leukemia, malignant peripheral nervesheath tumors and ovarian cancer, where SIX1 and EYA are both overexpressed 16, 21, 24, 27, [29] [30] [31] [32] . Further analysis of expression of SIX and EYA genes in the Oncomine database demonstrates that SIX1 and EYA genes are significantly overexpressed in numerous additional tumor types (Supplementary Table 1) , which suggests that inhibition of the SIX1-EYA transcriptional complex may be a broad anticancer therapeutic approach. Notably, overexpression of SIX1 and EYA genes correlates with decreased overall survival in brain, breast, head-neck, lung and pancreatic carcinomas as well as lymphoma ( Supplementary Table 1 ). High expression of SIX1 and EYA genes also correlates with recurrence in glioblastoma, breast and ovarian carcinomas; with metastasis in breast, prostate and head-neck carcinomas as well as melanoma; with higher-grade malignancies in bladder, breast, colon, hepatocellular and endometrial carcinomas; and with more advanced stage in breast, cervical, colon, head and neck, lung and ovarian carcinomas ( Supplementary Table 1 ). Because the SIX1-EYA transcriptional complex is highly expressed during development, downregulated in adults and re-expressed in many tumor types, inhibiting the SIX1-EYA interaction may be a unique approach to inhibit tumor progression, while conferring limited side effects, for the many tumor types that overexpress this complex.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Structural data and coordinates for MBP-SIX1 in complex with EYA2ED have been deposited in the PDB, with accession number 4EGC.
Note: Supplementary information is available in the online version of the paper.
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